Abstract
Macrobiomolecular treatments for ocular inflammatory diseases have been described in a previous review. This article mainly discusses the application of small molecules in uveitis therapy, which includes corticosteroids, salicylic acid (aspirin), metabolite analogs, and anti-oxidative agents. Additionally, we update recent advances in peptide and nucleic acid related therapies, and focus mainly on the calcineurin inhibitor, cyclosporine, oral tolerant retinal proteins/peptides, gene therapy and ribonucleic acid interference strategies. We classify these immunomodulatory agents by their molecular signatures and highlight the molecular structure and mechanisms of function. These developments in understanding molecular mechanisms of the diseases, with the advent of new technologies, advance current therapeutic approaches. The future direction is to tailor treatments to individual patients in order to provide the safest and most effective therapies for ocular inflammatory diseases.
Keywords: Uveitis, macrobiomolecule, small molecule, immunosuppresion, anti-inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Application of Small Molecules/Macromolecules in Ocular Inflammatory Diseases
Volume: 11 Issue: 2
Author(s): Baoying Liu, Chi-Chao Chan and Robert B. Nussenblatt
Affiliation:
Keywords: Uveitis, macrobiomolecule, small molecule, immunosuppresion, anti-inflammation
Abstract: Macrobiomolecular treatments for ocular inflammatory diseases have been described in a previous review. This article mainly discusses the application of small molecules in uveitis therapy, which includes corticosteroids, salicylic acid (aspirin), metabolite analogs, and anti-oxidative agents. Additionally, we update recent advances in peptide and nucleic acid related therapies, and focus mainly on the calcineurin inhibitor, cyclosporine, oral tolerant retinal proteins/peptides, gene therapy and ribonucleic acid interference strategies. We classify these immunomodulatory agents by their molecular signatures and highlight the molecular structure and mechanisms of function. These developments in understanding molecular mechanisms of the diseases, with the advent of new technologies, advance current therapeutic approaches. The future direction is to tailor treatments to individual patients in order to provide the safest and most effective therapies for ocular inflammatory diseases.
Export Options
About this article
Cite this article as:
Liu Baoying, Chan Chi-Chao and B. Nussenblatt Robert, Application of Small Molecules/Macromolecules in Ocular Inflammatory Diseases, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2012; 11 (2) . https://dx.doi.org/10.2174/187152312803305713
DOI https://dx.doi.org/10.2174/187152312803305713 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Targeting Viral Proteases for the Discovery of Novel Antivirals
Current Topics in Medicinal Chemistry Synthesis of Combretastatin A-4 Analogs and their Biological Activities
Anti-Cancer Agents in Medicinal Chemistry Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Current Pharmaceutical Design Advances in Mitotic Inhibitors for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects
Mini-Reviews in Medicinal Chemistry Targeting Signaling Pathways in Multiple Myeloma
Current Pharmaceutical Biotechnology An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews Editorial
Current Pharmaceutical Biotechnology Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data
Current Drug Targets Neutrophil Extracellular Traps as a Drug Target to Counteract Chronic and Acute Inflammation
Current Pharmaceutical Biotechnology Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19
Current Drug Metabolism Physicochemical Characterization of Curcumin Loaded Chitosan Nanoparticles: Implications in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Mitochondria and Familial Predisposition to Breast Cancer
Current Genomics Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Recent Patents in Antiviral siRNAs
Recent Patents on Anti-Infective Drug Discovery Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma
Current Pharmaceutical Biotechnology